minocycline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, protein-synthesis inhibitors, tetracycline derivatives 1813 10118-90-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • minocycline
  • minocycline hydrochloride
  • minocycline HCl
A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.
  • Molecular weight: 457.48
  • Formula: C23H27N3O7
  • CLOGP: 0.05
  • LIPINSKI: 0
  • HAC: 10
  • HDO: 5
  • TPSA: 164.63
  • ALOGS: -2.17
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 mg O
0.20 g O
0.20 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 11 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.87 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 97 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 17 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 30, 1971 FDA TRIAX PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Exostosis 454.22 15.69 195 25664 17667 63445496
Bone erosion 452.45 15.69 194 25665 17523 63445640
Joint dislocation 441.38 15.69 194 25665 18606 63444557
Foot deformity 368.78 15.69 194 25665 27659 63435504
Polyarteritis nodosa 332.57 15.69 63 25796 228 63462935
Lupus-like syndrome 317.98 15.69 145 25714 15150 63448013
Joint stiffness 307.63 15.69 199 25660 41670 63421493
Retinitis 292.93 15.69 106 25753 6090 63457073
Osteoporosis 277.47 15.69 211 25648 57127 63406036
Hepatic cirrhosis 273.70 15.69 153 25706 24581 63438582
Osteoarthritis 222.25 15.69 232 25627 95111 63368052
Drug intolerance 217.68 15.69 423 25436 308238 63154925
Laryngitis 198.77 15.69 109 25750 16858 63446305
Idiopathic intracranial hypertension 188.13 15.69 63 25796 2868 63460295
Drug reaction with eosinophilia and systemic symptoms 164.65 15.69 125 25734 33711 63429452
Arthritis 154.14 15.69 212 25647 115709 63347454
Red blood cell sedimentation rate increased 143.83 15.69 129 25730 43853 63419310
Adverse drug reaction 136.05 15.69 165 25694 79549 63383614
General physical health deterioration 129.61 15.69 266 25593 201136 63262027
Drug ineffective 128.19 15.69 792 25067 1043973 62419190
Ear infection 122.81 15.69 111 25748 38102 63425061
Ochronosis 119.06 15.69 20 25839 27 63463136
C-reactive protein increased 115.15 15.69 166 25693 94541 63368622
Drug-induced liver injury 114.12 15.69 109 25750 40113 63423050
Skin hyperpigmentation 113.23 15.69 53 25806 5868 63457295
Gastric disorder 109.32 15.69 103 25756 37266 63425897
Thyroiditis 101.09 15.69 38 25821 2428 63460735
Rheumatoid arthritis 91.20 15.69 268 25591 253551 63209612
Drug hypersensitivity 90.48 15.69 305 25554 310382 63152781
Mobility decreased 89.90 15.69 170 25689 120989 63342174
Eosinophilic myocarditis 81.03 15.69 23 25836 597 63462566
Lupus vulgaris 77.13 15.69 41 25818 5953 63457210
Hypercholesterolaemia 76.57 15.69 66 25793 21268 63441895
Therapeutic product effect incomplete 73.16 15.69 159 25700 124897 63338266
Joint swelling 69.79 15.69 291 25568 327375 63135788
Visual impairment 68.28 15.69 123 25736 84323 63378840
Papilloedema 68.24 15.69 33 25826 3927 63459236
Hidradenitis 65.54 15.69 29 25830 2817 63460346
Synovitis 63.87 15.69 194 25665 186724 63276439
Type 2 diabetes mellitus 63.49 15.69 102 25757 63766 63399397
Asthenia 63.38 15.69 39 25820 383565 63079598
Vasculitis necrotising 60.93 15.69 18 25841 540 63462623
Hepatic enzyme increased 60.00 15.69 200 25659 202128 63261035
Pigmentation disorder 57.63 15.69 31 25828 4608 63458555
Dyspepsia 57.56 15.69 128 25731 102068 63361095
Treatment failure 57.47 15.69 195 25664 198848 63264315
Sleep disorder 57.46 15.69 112 25747 81454 63381709
Scleral pigmentation 56.66 15.69 9 25850 6 63463157
Death 56.57 15.69 42 25817 374339 63088824
Bone hyperpigmentation 54.54 15.69 9 25850 10 63463153
Abdominal distension 53.94 15.69 113 25746 86502 63376661
Product use in unapproved indication 53.06 15.69 177 25682 178903 63284260
Intracranial pressure increased 51.51 15.69 30 25829 5197 63457966
Conjunctival pigmentation 51.22 15.69 10 25849 44 63463119
Adverse reaction 50.28 15.69 38 25821 10165 63452998
Anti-cyclic citrullinated peptide antibody positive 49.83 15.69 131 25728 116081 63347082
Hypoaesthesia 49.50 15.69 166 25693 168227 63294936
Rheumatoid factor positive 47.84 15.69 106 25753 84300 63378863
Blood cholesterol increased 47.67 15.69 113 25746 93919 63369244
Optic atrophy 46.31 15.69 18 25841 1260 63461903
Onychomadesis 45.92 15.69 29 25830 5811 63457352
Toxicity to various agents 45.36 15.69 22 25837 247228 63215935
Pericarditis 45.31 15.69 137 25722 131442 63331721
Product label confusion 43.36 15.69 19 25840 1803 63461360
Eosinophilic pneumonia acute 43.29 15.69 13 25846 413 63462750
Hypotension 43.23 15.69 29 25830 272575 63190588
Rheumatic fever 43.04 15.69 69 25790 43042 63420121
Decreased appetite 41.46 15.69 207 25652 250845 63212318
Dyspnoea 40.76 15.69 136 25723 661177 62801986
Back pain 40.69 15.69 29 25830 264116 63199047
Onychomycosis 40.10 15.69 30 25829 7902 63455261
Drug interaction 39.63 15.69 22 25837 229109 63234054
Arthralgia 38.91 15.69 378 25481 569332 62893831
Nail disorder 36.38 15.69 35 25824 12980 63450183
Dermatitis acneiform 34.82 15.69 23 25836 4973 63458190
Paronychia 32.57 15.69 23 25836 5542 63457621
Musculoskeletal stiffness 32.44 15.69 155 25704 184463 63278700
Urinary tract infection 32.42 15.69 36 25823 264648 63198515
Fall 32.18 15.69 70 25789 392264 63070899
Diarrhoea 31.72 15.69 167 25692 715199 62747964
Hand deformity 31.06 15.69 138 25721 159319 63303844
Henoch-Schonlein purpura 30.54 15.69 13 25846 1150 63462013
Cough 30.49 15.69 45 25814 292698 63170465
Completed suicide 29.84 15.69 11 25848 145662 63317501
Constipation 29.34 15.69 29 25830 224914 63238249
Barotrauma 29.27 15.69 8 25851 180 63462983
Product dose omission issue 28.55 15.69 32 25827 234281 63228882
Enterococcal sepsis 28.06 15.69 13 25846 1405 63461758
Sinusitis 27.56 15.69 31 25828 226622 63236541
Hepatic function abnormal 27.36 15.69 52 25807 37090 63426073
Contraindicated product administered 26.90 15.69 166 25693 217482 63245681
Arteritis 26.55 15.69 10 25849 642 63462521
Wound 26.48 15.69 134 25725 163129 63300034
Skin odour abnormal 26.07 15.69 13 25846 1653 63461510
Coeliac disease 26.00 15.69 29 25830 12768 63450395
Haemoglobin decreased 25.10 15.69 14 25845 145471 63317692
Systemic lupus erythematosus 24.36 15.69 157 25702 208761 63254402
Acute kidney injury 24.15 15.69 44 25815 263371 63199792
Thyroiditis acute 23.71 15.69 6 25853 99 63463064
Hepatitis 23.70 15.69 51 25808 39737 63423426
Type 2 lepra reaction 23.65 15.69 5 25854 35 63463128
Retinal pigmentation 23.59 15.69 6 25853 101 63463062
Off label use 23.45 15.69 395 25464 674067 62789096
Back injury 23.34 15.69 24 25835 9636 63453527
Tooth discolouration 22.73 15.69 10 25849 958 63462205
Anaemia 22.70 15.69 54 25805 293376 63169787
Helicobacter infection 22.55 15.69 86 25773 92699 63370464
Glossodynia 22.45 15.69 137 25722 178739 63284424
Psoriatic arthropathy 22.39 15.69 85 25774 91435 63371728
Condition aggravated 22.27 15.69 256 25603 401961 63061202
Finger deformity 21.97 15.69 21 25838 7724 63455439
Atrial fibrillation 21.95 15.69 10 25849 116626 63346537
Abdominal pain 21.92 15.69 55 25804 293401 63169762
Therapeutic product effect decreased 21.80 15.69 144 25715 193043 63270120
Fibromyalgia 21.61 15.69 77 25782 80343 63382820
Pemphigus 21.37 15.69 138 25721 183588 63279575
Grip strength decreased 21.33 15.69 35 25824 22252 63440911
Peripheral swelling 21.32 15.69 48 25811 265894 63197269
Infection 21.31 15.69 163 25696 229010 63234153
Hyperthyroidism 21.23 15.69 28 25831 14645 63448518
Oedema peripheral 21.22 15.69 141 25718 189370 63273793
Cerebrovascular accident 20.74 15.69 9 25850 108015 63355148
Monocytosis 20.66 15.69 8 25851 554 63462609
Weight decreased 20.57 15.69 52 25807 276746 63186417
Anti-cyclic citrullinated peptide antibody 20.46 15.69 19 25840 6739 63456424
Post inflammatory pigmentation change 20.38 15.69 7 25852 344 63462819
Neutropenia 20.13 15.69 25 25834 174980 63288183
Pustule 20.12 15.69 11 25848 1688 63461475
Infusion related reaction 19.77 15.69 169 25690 245352 63217811
Weight increased 19.37 15.69 49 25810 260743 63202420
Tuberculin test positive 19.37 15.69 14 25845 3497 63459666
Injection site erythema 19.33 15.69 5 25854 83169 63379994
Somnolence 19.05 15.69 27 25832 178658 63284505
Hyponatraemia 18.96 15.69 11 25848 111889 63351274
Injury 18.72 15.69 69 25790 73178 63389985
Flushing 18.46 15.69 4 25855 75083 63388080
Adverse event 18.42 15.69 65 25794 67494 63395669
Dehiscence 18.40 15.69 5 25854 110 63463053
Influenza 17.98 15.69 11 25848 108711 63354452
COVID-19 17.95 15.69 12 25847 113091 63350072
Bradycardia 17.80 15.69 4 25855 73223 63389940
Antinuclear antibody positive 17.77 15.69 19 25840 7980 63455183
Pigment nephropathy 17.74 15.69 4 25855 39 63463124
Dehydration 17.69 15.69 27 25832 173327 63289836
Mononeuropathy multiplex 17.65 15.69 6 25853 286 63462877
Blood creatinine increased 17.38 15.69 7 25852 87837 63375326
Antinuclear antibody increased 16.87 15.69 9 25850 1316 63461847
Malaise 16.82 15.69 250 25609 415704 63047459
Mononeuropathy 16.68 15.69 5 25854 158 63463005
Discomfort 16.65 15.69 121 25738 167253 63295910
Injection site pain 16.61 15.69 17 25842 129783 63333380
Hyperhidrosis 16.37 15.69 12 25847 107824 63355339
Cardiovascular disorder 16.26 15.69 22 25837 11790 63451373
Overdose 15.98 15.69 14 25845 115064 63348099
Depressed level of consciousness 15.90 15.69 3 25856 62075 63401088
Nasopharyngitis 15.79 15.69 52 25807 254205 63208958

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Apparent death 228.41 20.25 70 9555 3574 34943732
Photosensitivity reaction 218.51 20.25 89 9536 10505 34936801
Red blood cell sedimentation rate increased 202.84 20.25 81 9544 9081 34938225
Terminal state 202.44 20.25 65 9560 3869 34943437
C-reactive protein abnormal 189.34 20.25 76 9549 8634 34938672
Interstitial lung disease 189.28 20.25 151 9474 65131 34882175
Skin hyperpigmentation 184.77 20.25 58 9567 3206 34944100
Pulmonary thrombosis 183.34 20.25 71 9554 7336 34939970
Stomatitis 181.03 20.25 124 9501 42390 34904916
Intestinal sepsis 143.56 20.25 34 9591 637 34946669
Polyarteritis nodosa 140.71 20.25 29 9596 275 34947031
Pigmentation disorder 136.10 20.25 43 9582 2426 34944880
Diverticulitis 129.23 20.25 76 9549 19928 34927378
Scleral pigmentation 122.38 20.25 17 9608 0 34947306
Dermatitis acneiform 120.78 20.25 50 9575 6139 34941167
Herpes zoster 117.95 20.25 88 9537 34311 34912995
Joint arthroplasty 114.48 20.25 30 9595 861 34946445
Contraindicated product administered 106.63 20.25 69 9556 21412 34925894
Urticaria 95.48 20.25 101 9524 62276 34885030
Bone hyperpigmentation 94.45 20.25 14 9611 8 34947298
Joint swelling 91.71 20.25 97 9528 59793 34887513
C-reactive protein increased 88.89 20.25 91 9534 54007 34893299
Arthropathy 88.13 20.25 67 9558 26840 34920466
Thrombosis 83.11 20.25 85 9540 50373 34896933
Paronychia 81.96 20.25 32 9593 3373 34943933
Ochronosis 79.18 20.25 11 9614 0 34947306
Feeling abnormal 78.85 20.25 92 9533 63143 34884163
Knee arthroplasty 75.07 20.25 38 9587 7406 34939900
Drug intolerance 73.15 20.25 86 9539 59484 34887822
Thyroiditis 70.58 20.25 26 9599 2336 34944970
Deep vein thrombosis 70.04 20.25 88 9537 65160 34882146
Pulmonary embolism 66.21 20.25 101 9524 89645 34857661
Drug hypersensitivity 65.68 20.25 95 9530 80434 34866872
Stent placement 63.42 20.25 30 9595 5048 34942258
Anti-neutrophil cytoplasmic antibody positive vasculitis 58.84 20.25 18 9607 911 34946395
Drug reaction with eosinophilia and systemic symptoms 53.21 20.25 55 9570 32957 34914349
Intentional product use issue 50.84 20.25 72 9553 59744 34887562
Scleral discolouration 49.36 20.25 12 9613 252 34947054
Haemoglobin decreased 44.70 20.25 101 9524 120671 34826635
Drug ineffective 42.88 20.25 242 9383 456509 34490797
Renal failure 42.67 20.25 104 9521 130453 34816853
Thyroiditis acute 42.04 20.25 9 9616 104 34947202
Retinal pigmentation 40.13 20.25 6 9619 4 34947302
Autoimmune thyroiditis 39.09 20.25 14 9611 1160 34946146
Glomerulonephritis rapidly progressive 38.51 20.25 12 9613 646 34946660
Sepsis 36.83 20.25 115 9510 166446 34780860
Skin discolouration 36.73 20.25 34 9591 17811 34929495
Cardiac valve discolouration 35.99 20.25 5 9620 0 34947306
Serum sickness-like reaction 33.91 20.25 8 9617 147 34947159
Death 32.70 20.25 37 9588 398012 34549294
Vasculitis 32.35 20.25 26 9599 11270 34936036
Pemphigoid 31.52 20.25 23 9602 8643 34938663
Acute febrile neutrophilic dermatosis 30.49 20.25 12 9613 1291 34946015
Skin depigmentation 29.98 20.25 9 9616 427 34946879
Red blood cell sedimentation rate abnormal 29.55 20.25 16 9609 3573 34943733
Tissue discolouration 28.79 20.25 4 9621 0 34947306
Gingival hyperpigmentation 28.79 20.25 4 9621 0 34947306
Hepatic function abnormal 28.61 20.25 47 9578 44316 34902990
Eosinophilic pneumonia acute 28.02 20.25 9 9616 535 34946771
Hyperthyroidism 27.49 20.25 23 9602 10543 34936763
Peripheral sensory neuropathy 27.02 20.25 19 9606 6741 34940565
Nail discolouration 26.10 20.25 10 9615 1001 34946305
IIIrd nerve paralysis 24.30 20.25 8 9617 514 34946792
Melanocytic naevus 23.73 20.25 12 9613 2332 34944974
Myocardial infarction 23.48 20.25 80 9545 121005 34826301
Testicular infarction 23.42 20.25 5 9620 57 34947249
Pharyngeal inflammation 23.36 20.25 7 9618 330 34946976
Jarisch-Herxheimer reaction 23.33 20.25 8 9617 583 34946723
Dyspnoea 23.07 20.25 43 9582 376739 34570567
Protein total abnormal 23.04 20.25 7 9618 346 34946960
Post procedural infection 22.61 20.25 15 9610 4841 34942465
Testicular pain 21.65 20.25 12 9613 2806 34944500
Joint deposit 21.59 20.25 3 9622 0 34947306
Hypotension 21.15 20.25 18 9607 221631 34725675
Tooth injury 21.04 20.25 9 9616 1196 34946110
Breast inflammation 20.36 20.25 4 9621 29 34947277
Thyroid disorder 20.29 20.25 12 9613 3170 34944136

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Polyarteritis nodosa 415.13 14.80 83 30088 462 79713755
Exostosis 296.01 14.80 139 30032 16719 79697498
Joint dislocation 295.38 14.80 139 30032 16800 79697417
Lupus-like syndrome 292.89 14.80 130 30041 13727 79700490
Bone erosion 288.46 14.80 139 30032 17708 79696509
Skin hyperpigmentation 287.19 14.80 107 30064 7196 79707021
Red blood cell sedimentation rate increased 263.27 14.80 182 29989 45760 79668457
Retinitis 252.73 14.80 91 30080 5552 79708665
Foot deformity 251.94 14.80 140 30031 23934 79690283
Drug intolerance 224.79 14.80 377 29794 263742 79450475
Joint stiffness 206.72 14.80 150 30021 40680 79673537
Drug reaction with eosinophilia and systemic symptoms 199.11 14.80 177 29994 64067 79650150
Hepatic cirrhosis 194.60 14.80 136 30035 34770 79679447
Apparent death 185.99 14.80 61 30110 2804 79711413
Pigmentation disorder 180.32 14.80 71 30100 5547 79708670
Ochronosis 176.59 14.80 29 30142 35 79714182
Osteoporosis 175.50 14.80 153 30018 53959 79660258
Laryngitis 169.78 14.80 94 30077 15945 79698272
Scleral pigmentation 159.78 14.80 24 30147 6 79714211
Thyroiditis 157.70 14.80 61 30110 4544 79709673
Terminal state 147.19 14.80 59 30112 4830 79709387
C-reactive protein increased 147.11 14.80 211 29960 128816 79585401
Drug ineffective 142.23 14.80 791 29380 1080122 78634095
Joint swelling 139.42 14.80 325 29846 288321 79425896
Drug hypersensitivity 138.35 14.80 331 29840 298585 79415632
Dermatitis acneiform 138.15 14.80 70 30101 9923 79704294
Bone hyperpigmentation 135.15 14.80 22 30149 24 79714193
Photosensitivity reaction 124.04 14.80 85 30086 21042 79693175
Gastric disorder 121.66 14.80 106 30065 37327 79676890
Idiopathic intracranial hypertension 118.64 14.80 45 30126 3177 79711040
Osteoarthritis 117.90 14.80 155 30016 87154 79627063
Contraindicated product administered 114.45 14.80 210 29961 157328 79556889
Pulmonary thrombosis 109.10 14.80 64 30107 12107 79702110
Ear infection 108.88 14.80 96 30075 34336 79679881
Paronychia 108.83 14.80 55 30116 7753 79706464
Adverse drug reaction 104.10 14.80 127 30044 66265 79647952
Drug-induced liver injury 99.68 14.80 124 30047 65993 79648224
Eosinophilic pneumonia acute 98.82 14.80 30 30141 1068 79713149
Interstitial lung disease 98.57 14.80 163 30008 112437 79601780
Synovitis 97.19 14.80 191 29980 150543 79563674
Intestinal sepsis 95.85 14.80 28 30143 871 79713346
Stomatitis 94.67 14.80 186 29985 146571 79567646
Arthritis 88.31 14.80 157 30014 114723 79599494
C-reactive protein abnormal 88.24 14.80 100 30071 48267 79665950
Treatment failure 87.74 14.80 197 29974 170289 79543928
Rheumatoid arthritis 85.91 14.80 221 29950 208249 79505968
Joint arthroplasty 82.25 14.80 33 30138 2707 79711510
Toxicity to various agents 77.99 14.80 31 30140 421509 79292708
Anti-cyclic citrullinated peptide antibody positive 77.69 14.80 124 30047 83019 79631198
Hypotension 77.27 14.80 35 30136 440282 79273935
General physical health deterioration 72.55 14.80 249 29922 274989 79439228
Death 72.15 14.80 65 30106 566449 79147768
Systemic lupus erythematosus 71.49 14.80 148 30023 121001 79593216
Pemphigus 70.07 14.80 131 30040 99451 79614766
Rheumatoid factor positive 69.80 14.80 99 30072 59740 79654477
Eosinophilic myocarditis 67.33 14.80 23 30148 1199 79713018
Rheumatic fever 66.18 14.80 67 30104 28458 79685759
Vasculitis necrotising 65.94 14.80 23 30148 1277 79712940
Drug interaction 65.39 14.80 38 30133 415145 79299072
Hand deformity 64.92 14.80 130 30041 103789 79610428
Mobility decreased 64.88 14.80 143 30028 122032 79592185
Pericarditis 64.64 14.80 130 30041 104106 79610111
Thyroiditis acute 64.35 14.80 15 30156 186 79714031
Glossodynia 64.23 14.80 129 30042 103208 79611009
Lupus vulgaris 63.09 14.80 29 30142 3317 79710900
Hidradenitis 62.51 14.80 28 30143 3016 79711201
Dyspnoea 61.49 14.80 147 30024 856878 78857339
Completed suicide 60.80 14.80 10 30161 245757 79468460
Adverse reaction 60.72 14.80 40 30131 9274 79704943
Asthenia 59.04 14.80 64 30107 511625 79202592
Sleep disorder 56.92 14.80 110 30061 85567 79628650
Dyspepsia 56.33 14.80 126 30045 108561 79605656
Wound 56.14 14.80 131 30040 116048 79598169
Onychomadesis 53.49 14.80 30 30141 5212 79709005
Hepatic enzyme increased 53.23 14.80 171 30000 182439 79531778
Scleral discolouration 51.98 14.80 16 30155 597 79713620
Conjunctival pigmentation 51.96 14.80 10 30161 44 79714173
Visual impairment 51.37 14.80 110 30061 92021 79622196
Anti-neutrophil cytoplasmic antibody positive vasculitis 51.18 14.80 26 30145 3703 79710514
Product label confusion 46.80 14.80 19 30152 1607 79712610
Hepatic function abnormal 46.30 14.80 92 30079 73015 79641202
Hyperthyroidism 44.08 14.80 48 30123 22161 79692056
Onychomycosis 43.26 14.80 31 30140 8230 79705987
Serum sickness-like reaction 43.16 14.80 14 30157 621 79713596
Therapeutic product effect incomplete 42.50 14.80 134 30037 141511 79572706
Drug abuse 41.64 14.80 6 30165 162685 79551532
Abdominal distension 41.37 14.80 119 30052 119531 79594686
Diverticulitis 40.83 14.80 67 30104 45869 79668348
Musculoskeletal stiffness 39.82 14.80 151 30020 174857 79539360
Back pain 38.53 14.80 35 30136 304145 79410072
Therapeutic product effect decreased 37.79 14.80 142 30029 163721 79550496
Knee arthroplasty 36.99 14.80 62 30109 43186 79671031
Cough 35.86 14.80 52 30119 366737 79347480
Product dose omission issue 35.72 14.80 25 30146 247512 79466705
Gingival hyperpigmentation 35.40 14.80 6 30165 10 79714207
Type 2 diabetes mellitus 35.10 14.80 71 30100 57051 79657166
Retinal pigmentation 34.56 14.80 8 30163 96 79714121
Cardiac valve discolouration 34.40 14.80 5 30166 0 79714217
Acute febrile neutrophilic dermatosis 33.75 14.80 20 30151 3852 79710365
Blood cholesterol increased 33.65 14.80 88 30083 83632 79630585
Urticaria 33.59 14.80 149 30022 185052 79529165
Nail disorder 33.43 14.80 31 30140 11821 79702396
Papilloedema 31.75 14.80 23 30148 6210 79708007
Acute kidney injury 31.20 14.80 97 30074 519307 79194910
Product use in unapproved indication 31.05 14.80 181 29990 250178 79464039
Mononeuropathy multiplex 30.90 14.80 10 30161 440 79713777
Stent placement 30.82 14.80 23 30148 6497 79707720
Fall 30.04 14.80 90 30081 487539 79226678
Discomfort 29.90 14.80 110 30061 125507 79588710
Liver injury 29.73 14.80 66 30105 56548 79657669
Barotrauma 29.36 14.80 8 30163 192 79714025
Infection 28.85 14.80 173 29998 241539 79472678
Coeliac disease 28.80 14.80 28 30143 11323 79702894
Arthropathy 28.79 14.80 138 30033 176973 79537244
Overdose 28.76 14.80 17 30154 184189 79530028
Mononeuropathy 28.75 14.80 8 30163 208 79714009
Decreased appetite 28.35 14.80 224 29947 342194 79372023
Psoriatic arthropathy 28.34 14.80 79 30092 77920 79636297
Neutropenia 27.90 14.80 41 30130 287669 79426548
Coma 27.48 14.80 3 30168 100646 79613571
Somnolence 27.38 14.80 30 30141 238951 79475266
Atrial fibrillation 27.22 14.80 21 30150 197865 79516352
Cardiac failure congestive 27.07 14.80 10 30161 142392 79571825
Vasculitis 27.03 14.80 40 30131 25062 79689155
Thrombosis 26.54 14.80 81 30090 84019 79630198
Weight increased 26.44 14.80 40 30131 277346 79436871
Cerebrovascular accident 26.18 14.80 13 30158 155279 79558938
Intracranial pressure increased 25.89 14.80 23 30148 8299 79705918
Urinary tract infection 25.76 14.80 40 30131 274472 79439745
Deep vein thrombosis 25.59 14.80 102 30069 120817 79593400
Type 1 diabetes mellitus 25.35 14.80 21 30150 6898 79707319
Tissue discolouration 25.28 14.80 4 30167 3 79714214
Herpes zoster 25.15 14.80 85 30086 92998 79621219
Hypercholesterolaemia 25.15 14.80 37 30134 23058 79691159
Tooth discolouration 24.90 14.80 11 30160 1146 79713071
Alopecia 24.74 14.80 161 30010 231194 79483023
Hypoaesthesia 24.43 14.80 133 30038 179219 79534998
Arthralgia 24.22 14.80 326 29845 571477 79142740
Glomerulonephritis rapidly progressive 24.11 14.80 12 30159 1636 79712581
Anti-cyclic citrullinated peptide antibody 24.06 14.80 19 30152 5833 79708384
Finger deformity 23.94 14.80 21 30150 7453 79706764
Swollen joint count increased 23.92 14.80 36 30135 22891 79691326
Type 2 lepra reaction 23.86 14.80 7 30164 221 79713996
Arteritis 23.86 14.80 10 30161 917 79713300
Peripheral sensory neuropathy 23.85 14.80 27 30144 13006 79701211
Jarisch-Herxheimer reaction 23.55 14.80 10 30161 947 79713270
Pemphigoid 23.51 14.80 29 30142 15286 79698931
Hyponatraemia 23.06 14.80 20 30151 177828 79536389
Intentional product use issue 22.91 14.80 116 30055 151996 79562221
Off label use 22.85 14.80 475 29696 906740 78807477
Autoimmune thyroiditis 22.43 14.80 16 30155 4217 79710000
Grip strength decreased 22.34 14.80 34 30137 21835 79692382
Confusional state 22.33 14.80 55 30116 317942 79396275
Vomiting 22.29 14.80 154 30017 665674 79048543
Tremor 22.21 14.80 19 30152 170064 79544153
Testicular infarction 21.83 14.80 5 30166 57 79714160
Skin discolouration 21.72 14.80 48 30123 40986 79673231
Testicular pain 21.56 14.80 12 30159 2053 79712164
Back injury 21.33 14.80 23 30148 10500 79703717
Abdominal discomfort 21.28 14.80 165 30006 250562 79463655
Skin odour abnormal 21.16 14.80 12 30159 2129 79712088
Antinuclear antibody positive 21.03 14.80 20 30151 7870 79706347
Enterococcal sepsis 20.98 14.80 13 30158 2713 79711504
Hepatitis 20.79 14.80 57 30114 55670 79658547
Agitation 20.71 14.80 6 30165 99709 79614508
Joint deposit 20.64 14.80 3 30168 0 79714217
Abdominal pain 20.48 14.80 77 30094 389492 79324725
Bradycardia 20.47 14.80 13 30158 135544 79578673
Cardiac arrest 20.38 14.80 21 30150 172075 79542142
Hypersensitivity 20.31 14.80 169 30002 262070 79452147
Rash 20.23 14.80 319 29852 578039 79136178
Sinusitis 19.79 14.80 27 30144 195474 79518743
Monocytosis 19.70 14.80 9 30162 1015 79713202
Hyperhidrosis 19.68 14.80 17 30154 151475 79562742
Pharyngeal inflammation 19.65 14.80 9 30162 1021 79713196
Product use issue 19.45 14.80 141 30030 209681 79504536
Gingival discolouration 19.21 14.80 6 30165 235 79713982
COVID-19 18.94 14.80 19 30152 157655 79556562
Injection site pain 18.86 14.80 13 30158 129825 79584392
Blood pressure increased 18.70 14.80 32 30139 211328 79502889
Pulmonary embolism 18.67 14.80 120 30051 171534 79542683
Henoch-Schonlein purpura 18.55 14.80 12 30159 2698 79711519
Cardio-respiratory arrest 18.41 14.80 9 30162 108501 79605716
Drug ineffective for unapproved indication 17.73 14.80 51 30120 51187 79663030
Constipation 17.58 14.80 52 30119 282998 79431219
Inflammation 17.41 14.80 76 30095 93677 79620540
Chills 17.39 14.80 21 30150 160213 79554004
Nail pigmentation 17.32 14.80 6 30165 326 79713891
Protein total abnormal 17.29 14.80 7 30164 588 79713629
Pigment nephropathy 17.20 14.80 4 30167 49 79714168
Injury 16.89 14.80 66 30105 77430 79636787
Salt craving 16.58 14.80 4 30167 58 79714159
Death neonatal 16.43 14.80 7 30164 668 79713549
Anaemia 16.35 14.80 100 30071 444915 79269302
Influenza 16.29 14.80 15 30156 129591 79584626
Stress 16.15 14.80 5 30166 79607 79634610
Blood glucose increased 16.06 14.80 12 30159 114963 79599254
Chest pain 16.02 14.80 54 30117 282250 79431967
International normalised ratio increased 16.01 14.80 6 30165 84715 79629502
Skin depigmentation 16.00 14.80 8 30163 1102 79713115
Duodenal ulcer perforation 15.76 14.80 58 30113 66153 79648064
Peripheral swelling 15.70 14.80 51 30120 269566 79444651
Varicocele 15.62 14.80 3 30168 13 79714204
IIIrd nerve paralysis 15.45 14.80 8 30163 1185 79713032
Loss of consciousness 15.25 14.80 25 30146 167918 79546299
Wound secretion 15.21 14.80 15 30156 6173 79708044
Lactic acidosis 15.05 14.80 4 30167 70355 79643862
Infusion related reaction 15.04 14.80 143 30028 230094 79484123

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A01AB23 ALIMENTARY TRACT AND METABOLISM
STOMATOLOGICAL PREPARATIONS
STOMATOLOGICAL PREPARATIONS
Antiinfectives and antiseptics for local oral treatment
ATC D10AF07 DERMATOLOGICALS
ANTI-ACNE PREPARATIONS
ANTI-ACNE PREPARATIONS FOR TOPICAL USE
Antiinfectives for treatment of acne
ATC J01AA08 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
TETRACYCLINES
Tetracyclines
FDA CS M0021223 Tetracyclines
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
FDA EPC N0000175882 Tetracycline-class Drug
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:76971 Escherichia coli metabolites
CHEBI has role CHEBI:176497 geroprotectors
FDA PE N0000193995 Decreased Prothrombin Activity

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Trachoma indication 2576002 DOID:11265
Listeriosis indication 4241002 DOID:11573
Actinomycotic infection indication 11817007 DOID:8478
Gonorrhea indication 15628003 DOID:7551
Tularemia indication 19265001
Infection of skin AND/OR subcutaneous tissue indication 19824006
Gingivostomatitis indication 20607006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Granuloma inguinale indication 28867007 DOID:9113
Acute gonococcal urethritis indication 29864006
Bronchitis indication 32398004 DOID:6132
Sinusitis indication 36971009
Periodontitis indication 41565005 DOID:824
Gonorrhea of rectum indication 42746002
Plague indication 58750007 DOID:3482
Cholera indication 63650001 DOID:1498
Acute gonococcal endometritis indication 65295003 DOID:7527
Urinary tract infectious disease indication 68566005
Yaws indication 70647001 DOID:10371
Gonorrhea of pharynx indication 74372003
Rickettsialpox indication 75096007 DOID:11103
Ornithosis indication 75116005 DOID:11262
Brucellosis indication 75702008 DOID:11077
Syphilis indication 76272004
Acne vulgaris indication 88616000
Infection by Campylobacter fetus indication 111835002
Meningococcus carrier indication 170486006
Rocky Mountain spotted fever indication 186772009
Q fever indication 186788009 DOID:11100
Lymphogranuloma venereum indication 186946009 DOID:13819
Pneumonia indication 233604007 DOID:552
Inclusion conjunctivitis indication 266109000
Bartonellosis indication 266123003 DOID:11102
Chancroid indication 266143009 DOID:13778
Infective otitis media indication 312218008
Fusospirochetal pharyngitis indication 399095008
Pharyngitis indication 405737000 DOID:2275
Anthrax indication 409498004 DOID:7427
Relapsing fever indication 420079008 DOID:13034
Chlamydia trachomatis infection of genital structure indication 428015005
Rectal Chlamydia Trachomatis Infection indication
Ureaplasma Urealyticum Infections indication
Typhus Infections indication
Nocardiosis off-label use 29227009 DOID:2312
Enterocolitis off-label use 43752006
Pneumonia due to Mycoplasma pneumoniae off-label use 46970008
Rheumatoid arthritis off-label use 69896004 DOID:7148
Leprosy off-label use 81004002 DOID:1024
Cholangitis off-label use 82403002 DOID:9446
Mycobacteriosis off-label use 88415009
Chlamydial infection off-label use 105629000
Infectious disease of abdomen off-label use 128070006
Ocular rosacea off-label use 200933006
Benign intracranial hypertension contraindication 68267002 DOID:11459
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Esophageal dysmotility contraindication 266434009 DOID:9192
Pregnancy, function contraindication 289908002
Pseudomembranous enterocolitis contraindication 397683000
Breastfeeding (mother) contraindication 413712001
Azotemia contraindication 445009001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.13 acidic
pKa2 8.85 acidic
pKa3 11.14 acidic
pKa4 11.96 acidic
pKa5 13.08 acidic
pKa6 9.55 Basic
pKa7 4.82 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 105MG BASE SOLODYN BAUSCH N050808 Aug. 27, 2010 RX TABLET, EXTENDED RELEASE ORAL 7790705 June 24, 2025 TREATMENT OF ACNE
EQ 105MG BASE SOLODYN BAUSCH N050808 Aug. 27, 2010 RX TABLET, EXTENDED RELEASE ORAL 8252776 June 24, 2025 TREATMENT OF ACNE
EQ 105MG BASE SOLODYN BAUSCH N050808 Aug. 27, 2010 RX TABLET, EXTENDED RELEASE ORAL 8268804 June 24, 2025 TREATMENT OF ACNE
EQ 105MG BASE SOLODYN BAUSCH N050808 Aug. 27, 2010 RX TABLET, EXTENDED RELEASE ORAL 8722650 June 24, 2025 TREATMENT OF ACNE
EQ 115MG BASE SOLODYN BAUSCH N050808 July 23, 2009 RX TABLET, EXTENDED RELEASE ORAL 7790705 June 24, 2025 TREATMENT OF ACNE
EQ 115MG BASE SOLODYN BAUSCH N050808 July 23, 2009 RX TABLET, EXTENDED RELEASE ORAL 8252776 June 24, 2025 TREATMENT OF ACNE
EQ 115MG BASE SOLODYN BAUSCH N050808 July 23, 2009 RX TABLET, EXTENDED RELEASE ORAL 8268804 June 24, 2025 TREATMENT OF ACNE
EQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** SOLODYN BAUSCH N050808 May 8, 2006 DISCN TABLET, EXTENDED RELEASE ORAL 7790705 June 24, 2025 TREATMENT OF ACNE
EQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** SOLODYN BAUSCH N050808 May 8, 2006 DISCN TABLET, EXTENDED RELEASE ORAL 8252776 June 24, 2025 TREATMENT OF ACNE
EQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** SOLODYN BAUSCH N050808 May 8, 2006 DISCN TABLET, EXTENDED RELEASE ORAL 8268804 June 24, 2025 TREATMENT OF ACNE
EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** SOLODYN BAUSCH N050808 May 8, 2006 DISCN TABLET, EXTENDED RELEASE ORAL 7790705 June 24, 2025 TREATMENT OF ACNE
EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** SOLODYN BAUSCH N050808 May 8, 2006 DISCN TABLET, EXTENDED RELEASE ORAL 8252776 June 24, 2025 TREATMENT OF ACNE
EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** SOLODYN BAUSCH N050808 May 8, 2006 DISCN TABLET, EXTENDED RELEASE ORAL 8268804 June 24, 2025 TREATMENT OF ACNE
EQ 55MG BASE SOLODYN BAUSCH N050808 Aug. 27, 2010 RX TABLET, EXTENDED RELEASE ORAL 7790705 June 24, 2025 TREATMENT OF ACNE
EQ 55MG BASE SOLODYN BAUSCH N050808 Aug. 27, 2010 RX TABLET, EXTENDED RELEASE ORAL 8252776 June 24, 2025 TREATMENT OF ACNE
EQ 55MG BASE SOLODYN BAUSCH N050808 Aug. 27, 2010 RX TABLET, EXTENDED RELEASE ORAL 8268804 June 24, 2025 TREATMENT OF ACNE
EQ 55MG BASE SOLODYN BAUSCH N050808 Aug. 27, 2010 RX TABLET, EXTENDED RELEASE ORAL 8722650 June 24, 2025 TREATMENT OF ACNE
EQ 65MG BASE SOLODYN BAUSCH N050808 July 23, 2009 RX TABLET, EXTENDED RELEASE ORAL 7790705 June 24, 2025 TREATMENT OF ACNE
EQ 65MG BASE SOLODYN BAUSCH N050808 July 23, 2009 RX TABLET, EXTENDED RELEASE ORAL 8252776 June 24, 2025 TREATMENT OF ACNE
EQ 65MG BASE SOLODYN BAUSCH N050808 July 23, 2009 RX TABLET, EXTENDED RELEASE ORAL 8268804 June 24, 2025 TREATMENT OF ACNE
EQ 80MG BASE SOLODYN BAUSCH N050808 Aug. 27, 2010 RX TABLET, EXTENDED RELEASE ORAL 7790705 June 24, 2025 TREATMENT OF ACNE
EQ 80MG BASE SOLODYN BAUSCH N050808 Aug. 27, 2010 RX TABLET, EXTENDED RELEASE ORAL 8252776 June 24, 2025 TREATMENT OF ACNE
EQ 80MG BASE SOLODYN BAUSCH N050808 Aug. 27, 2010 RX TABLET, EXTENDED RELEASE ORAL 8268804 June 24, 2025 TREATMENT OF ACNE
EQ 80MG BASE SOLODYN BAUSCH N050808 Aug. 27, 2010 RX TABLET, EXTENDED RELEASE ORAL 8722650 June 24, 2025 TREATMENT OF ACNE
EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** SOLODYN BAUSCH N050808 May 8, 2006 DISCN TABLET, EXTENDED RELEASE ORAL 7790705 June 24, 2025 TREATMENT OF ACNE
EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** SOLODYN BAUSCH N050808 May 8, 2006 DISCN TABLET, EXTENDED RELEASE ORAL 8252776 June 24, 2025 TREATMENT OF ACNE
EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** SOLODYN BAUSCH N050808 May 8, 2006 DISCN TABLET, EXTENDED RELEASE ORAL 8268804 June 24, 2025 TREATMENT OF ACNE
EQ 135MG BASE XIMINO JOURNEY N201922 July 11, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7790705 June 24, 2025 TREATMENT OF ACNE
EQ 135MG BASE XIMINO JOURNEY N201922 July 11, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8252776 June 24, 2025 TREATMENT OF ACNE
EQ 135MG BASE XIMINO JOURNEY N201922 July 11, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8268804 June 24, 2025 TREATMENT OF ACNE
EQ 45MG BASE XIMINO JOURNEY N201922 July 11, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7790705 June 24, 2025 TREATMENT OF ACNE
EQ 45MG BASE XIMINO JOURNEY N201922 July 11, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8252776 June 24, 2025 TREATMENT OF ACNE
EQ 45MG BASE XIMINO JOURNEY N201922 July 11, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8268804 June 24, 2025 TREATMENT OF ACNE
EQ 90MG BASE XIMINO JOURNEY N201922 July 11, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7790705 June 24, 2025 TREATMENT OF ACNE
EQ 90MG BASE XIMINO JOURNEY N201922 July 11, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8252776 June 24, 2025 TREATMENT OF ACNE
EQ 90MG BASE XIMINO JOURNEY N201922 July 11, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 8268804 June 24, 2025 TREATMENT OF ACNE
EQ 105MG BASE SOLODYN BAUSCH N050808 Aug. 27, 2010 RX TABLET, EXTENDED RELEASE ORAL 7919483 March 7, 2027 TREATMENT OF ACNE
EQ 115MG BASE SOLODYN BAUSCH N050808 July 23, 2009 RX TABLET, EXTENDED RELEASE ORAL 7919483 March 7, 2027 TREATMENT OF ACNE
EQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** SOLODYN BAUSCH N050808 May 8, 2006 DISCN TABLET, EXTENDED RELEASE ORAL 7919483 March 7, 2027 TREATMENT OF ACNE
EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** SOLODYN BAUSCH N050808 May 8, 2006 DISCN TABLET, EXTENDED RELEASE ORAL 7919483 March 7, 2027 TREATMENT OF ACNE
EQ 55MG BASE SOLODYN BAUSCH N050808 Aug. 27, 2010 RX TABLET, EXTENDED RELEASE ORAL 7919483 March 7, 2027 TREATMENT OF ACNE
EQ 65MG BASE SOLODYN BAUSCH N050808 July 23, 2009 RX TABLET, EXTENDED RELEASE ORAL 7919483 March 7, 2027 TREATMENT OF ACNE
EQ 80MG BASE SOLODYN BAUSCH N050808 Aug. 27, 2010 RX TABLET, EXTENDED RELEASE ORAL 7919483 March 7, 2027 TREATMENT OF ACNE
EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** SOLODYN BAUSCH N050808 May 8, 2006 DISCN TABLET, EXTENDED RELEASE ORAL 7919483 March 7, 2027 TREATMENT OF ACNE
EQ 135MG BASE XIMINO JOURNEY N201922 July 11, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7919483 March 7, 2027 TREATMENT OF ACNE
EQ 45MG BASE XIMINO JOURNEY N201922 July 11, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7919483 March 7, 2027 TREATMENT OF ACNE
EQ 90MG BASE XIMINO JOURNEY N201922 July 11, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7919483 March 7, 2027 TREATMENT OF ACNE
EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** SOLODYN BAUSCH N050808 May 8, 2006 DISCN TABLET, EXTENDED RELEASE ORAL 7541347 April 2, 2027 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
EQ 135MG BASE XIMINO JOURNEY N201922 July 11, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7541347 April 2, 2027 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
EQ 45MG BASE XIMINO JOURNEY N201922 July 11, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7541347 April 2, 2027 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
EQ 90MG BASE XIMINO JOURNEY N201922 July 11, 2012 RX CAPSULE, EXTENDED RELEASE ORAL 7541347 April 2, 2027 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
EQ 4% BASE AMZEEQ JOURNEY N212379 Oct. 18, 2019 RX AEROSOL, FOAM TOPICAL 10086080 Oct. 1, 2030 TREATMENT OF NON-NODULAR ACNE VULGARIS
EQ 4% BASE AMZEEQ JOURNEY N212379 Oct. 18, 2019 RX AEROSOL, FOAM TOPICAL 10137200 Oct. 1, 2030 TREATMENT OF NON-NODULAR ACNE VULGARIS
EQ 4% BASE AMZEEQ JOURNEY N212379 Oct. 18, 2019 RX AEROSOL, FOAM TOPICAL 10213512 Oct. 1, 2030 TREATMENT OF NON-NODULAR ACNE VULGARIS
EQ 4% BASE AMZEEQ JOURNEY N212379 Oct. 18, 2019 RX AEROSOL, FOAM TOPICAL 10517882 Oct. 1, 2030 TREATMENT OF NON-NODULAR ACNE VULGARIS
EQ 4% BASE AMZEEQ JOURNEY N212379 Oct. 18, 2019 RX AEROSOL, FOAM TOPICAL 10821187 Oct. 1, 2030 TREATMENT OF NON-NODULAR ACNE VULGARIS
EQ 4% BASE AMZEEQ JOURNEY N212379 Oct. 18, 2019 RX AEROSOL, FOAM TOPICAL 8865139 Oct. 1, 2030 TREATMENT OF NON-NODULAR ACNE VULGARIS
EQ 4% BASE AMZEEQ JOURNEY N212379 Oct. 18, 2019 RX AEROSOL, FOAM TOPICAL 8992896 Oct. 1, 2030 TREATMENT OF NON-NODULAR ACNE VULGARIS
EQ 4% BASE AMZEEQ JOURNEY N212379 Oct. 18, 2019 RX AEROSOL, FOAM TOPICAL 9675700 Oct. 1, 2030 TREATMENT OF NON-NODULAR ACNE VULGARIS
EQ 1.5% BASE ZILXI JOURNEY N213690 May 28, 2020 RX AEROSOL, FOAM TOPICAL 10213512 Oct. 1, 2030 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
EQ 1.5% BASE ZILXI JOURNEY N213690 May 28, 2020 RX AEROSOL, FOAM TOPICAL 10322186 Oct. 1, 2030 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
EQ 1.5% BASE ZILXI JOURNEY N213690 May 28, 2020 RX AEROSOL, FOAM TOPICAL 10946101 Oct. 1, 2030 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
EQ 1.5% BASE ZILXI JOURNEY N213690 May 28, 2020 RX AEROSOL, FOAM TOPICAL 8865139 Oct. 1, 2030 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
EQ 1.5% BASE ZILXI JOURNEY N213690 May 28, 2020 RX AEROSOL, FOAM TOPICAL 8992896 Oct. 1, 2030 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
EQ 1.5% BASE ZILXI JOURNEY N213690 May 28, 2020 RX AEROSOL, FOAM TOPICAL 9675700 Oct. 1, 2030 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
EQ 100MG BASE/VIAL MINOCIN REMPEX N050444 None RX INJECTABLE INJECTION 9084802 May 12, 2031 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 100MG BASE/VIAL MINOCIN REMPEX N050444 None RX INJECTABLE INJECTION 9278105 May 12, 2031 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4% BASE AMZEEQ JOURNEY N212379 Oct. 18, 2019 RX AEROSOL, FOAM TOPICAL 10398641 Sept. 8, 2037 TREATMENT OF NON-NODULAR ACNE VULGARIS
EQ 4% BASE AMZEEQ JOURNEY N212379 Oct. 18, 2019 RX AEROSOL, FOAM TOPICAL 10849847 Sept. 8, 2037 TREATMENT OF NON-NODULAR ACNE VULGARIS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Tetracycline resistance protein, class B Transporter IC50 5.64 WOMBAT-PK
30S ribosomal protein S4 Ribosomal protein Ka 6 WOMBAT-PK
30S ribosomal protein S9 Ribosomal protein Ka 5.76 WOMBAT-PK

External reference:

IDSource
4019841 VUID
N0000147928 NUI
D00850 KEGG_DRUG
13614-98-7 SECONDARY_CAS_RN
4017916 VANDF
4019841 VANDF
C0026187 UMLSCUI
CHEBI:50694 CHEBI
MIY PDB_CHEM_ID
CHEMBL1434 ChEMBL_ID
CHEMBL1200881 ChEMBL_ID
D008911 MESH_DESCRIPTOR_UI
DB01017 DRUGBANK_ID
10831 IUPHAR_LIGAND_ID
1646 INN_ID
FYY3R43WGO UNII
54675783 PUBCHEM_CID
6979 RXNORM
1213 MMSL
21389 MMSL
5118 MMSL
d00110 MMSL
002754 NDDF
004864 NDDF
13512003 SNOMEDCT_US
372653009 SNOMEDCT_US
52886009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
minocycline hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-9935 TABLET, FILM COATED, EXTENDED RELEASE 65 mg ORAL NDA authorized generic 29 sections
minocycline hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-9935 TABLET, FILM COATED, EXTENDED RELEASE 65 mg ORAL NDA authorized generic 29 sections
minocycline hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-9936 TABLET, FILM COATED, EXTENDED RELEASE 115 mg ORAL NDA authorized generic 29 sections
minocycline hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-9936 TABLET, FILM COATED, EXTENDED RELEASE 115 mg ORAL NDA authorized generic 29 sections
Minocycline hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-7805 CAPSULE 100 mg ORAL ANDA 24 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-3153 CAPSULE 75 mg ORAL ANDA 26 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-5694 CAPSULE 50 mg ORAL ANDA 26 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-5695 CAPSULE 100 mg ORAL ANDA 26 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-5385 TABLET, EXTENDED RELEASE 45 mg ORAL ANDA 26 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-5386 TABLET, EXTENDED RELEASE 90 mg ORAL ANDA 26 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-5387 TABLET, EXTENDED RELEASE 135 mg ORAL ANDA 26 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6888 CAPSULE 100 mg ORAL ANDA 20 sections
Ximino HUMAN PRESCRIPTION DRUG LABEL 1 10631-330 CAPSULE, EXTENDED RELEASE 45 mg ORAL NDA 26 sections
Ximino HUMAN PRESCRIPTION DRUG LABEL 1 10631-331 CAPSULE, EXTENDED RELEASE 90 mg ORAL NDA 26 sections
Ximino HUMAN PRESCRIPTION DRUG LABEL 1 10631-332 CAPSULE, EXTENDED RELEASE 135 mg ORAL NDA 26 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-482 CAPSULE 50 mg ORAL ANDA 20 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-482 CAPSULE 50 mg ORAL ANDA 20 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-482 CAPSULE 50 mg ORAL ANDA 20 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-482 CAPSULE 50 mg ORAL ANDA 20 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-483 CAPSULE 75 mg ORAL ANDA 20 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-483 CAPSULE 75 mg ORAL ANDA 20 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-483 CAPSULE 75 mg ORAL ANDA 20 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-483 CAPSULE 75 mg ORAL ANDA 20 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-484 CAPSULE 100 mg ORAL ANDA 20 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-484 CAPSULE 100 mg ORAL ANDA 20 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-484 CAPSULE 100 mg ORAL ANDA 20 sections
Minocycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-484 CAPSULE 100 mg ORAL ANDA 20 sections
MINOCYCLINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 13668-485 TABLET 50 mg ORAL ANDA 14 sections
MINOCYCLINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 13668-485 TABLET 50 mg ORAL ANDA 14 sections
MINOCYCLINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 13668-485 TABLET 50 mg ORAL ANDA 14 sections